US bank ‘buy' on Smith & Nephew after better-than-expected results and $500m buyback

Smith & Nephew PLC reported stronger-than-expected Q2 results, with organic growth exceeding consensus by 200-250 basis points, driven by robust performance in joint repair, advanced wound biologics, and hips. The company also announced an unanticipated $500 million share buyback, projected by Citi to yield approximately 4% annualized EPS accretion, leading Citi to reiterate its 'buy' rating. Despite tariff impacts, S&N maintained its 2025 outlook for solid sales growth and improved operating margins, reinforcing investor confidence and contributing to a 0.7% stock increase.

Analysis

Smith & Nephew's second-quarter results significantly surpassed expectations, with organic growth exceeding consensus forecasts by 200-250 basis points, according to analysis from Citi. This outperformance was broad-based, with notable strength in the joint repair, advanced wound biologics, and hips segments, particularly highlighting continued momentum in US Orthopaedics. Management reinforced this positive operational narrative by maintaining its full-year 2025 guidance for solid sales growth and a stronger operating margin, demonstrating confidence in its ability to absorb an anticipated $15–20 million in tariffs. The announcement of an unexpected $500 million share buyback program serves as a significant additional catalyst, which Citi projects will generate approximately 4% in annualized earnings per share accretion at the current valuation, signaling strong confidence from the company in its cash flow generation and future prospects.

Key Decisions for Investors

• Given the substantial earnings beat and surprise capital return program, investors with a bullish outlook may consider the reaffirmed guidance a strong signal to build or add to positions.
• The announced $500 million buyback, implying a ~4% EPS accretion, should be factored into valuation models as a significant driver of shareholder return.
• Investors should monitor the performance of the US Orthopaedics division, cited as a key momentum driver, in subsequent quarters to validate the sustainability of the growth trajectory.
• While the company has absorbed tariff costs into its outlook, it remains a key risk factor to watch, ensuring it does not erode the guided margin expansion in future reporting.